Firm at a glance
Hildred Capital is a platform private equity firm headquartered in New York City, NY, with approximately $4 billion in assets under management as of January 2026 [S1].
What they buy
The firm’s portfolio demonstrates a concentrated focus on healthcare businesses across multiple subsectors [S2]. Observed investments span medical aesthetics, physical therapy, dermatology, pharmaceuticals, diagnostic technology, and healthcare software platforms [S2]. Recent acquisitions include both provider-facing technology and direct care delivery models, suggesting an appetite for healthcare services and enabling technology businesses [S3].
Portfolio
Healthcare
The firm’s portfolio consists exclusively of healthcare platform investments [S2]:
* OrangeTwist (platform, medical aesthetics)
* AleraCare (platform, home health)
* Carlin Consumer Health (platform, consumer health products)
* Healthcare.com (platform, healthcare marketplace)
* Binx Health (platform, diagnostics)
* identifeye HEALTH (platform, eye care)
* SportsMed Physical Therapy (platform, physical therapy services)
* Hyland’s Naturals (platform, natural remedies)
* DermCare Management (platform, dermatology)
* Columbia Care (platform, cannabis healthcare)
* Butterfly Network (platform, medical imaging)
* Pharmaceutics International, Inc (platform, pharmaceutical manufacturing)
* Revance (platform, aesthetics therapeutics)
* Tebra (platform, practice management software)
Recent activity (last 24 months)
* January 2026: Acquired OrangeTwist [S3]
* December 2025: Acquired Tebra [S3]
* November 2025: Acquired AleraCare and Pure Healthcare [S3]
* February 2025: Exited Revance Therapeutics [S3]
* February 2025: Exited Pharmaceutics International, Inc. [S3]
* January 2025: Closed Hildred Equity Partners III fund [S3]
* April 2024: Completed add-on acquisition for Carlin Consumer Health [S3]
* March 2024: Closed Multi-Asset Continuation Fund [S3]
How this firm fits a seller
Hildred Capital appears suited for healthcare business owners seeking a sector-focused buyer with demonstrated platform-building experience. The firm’s recent activity shows both acquisition momentum (three platform deals in late 2025 through early 2026) and exit execution (two portfolio company exits in early 2025), suggesting active portfolio management [S3]. The 2025 fund close indicates fresh capital availability for new investments [S3]. Healthcare services and technology businesses, particularly those in medical aesthetics, diagnostics, or provider services, align with the firm’s observed investment pattern [S2][S3].
Sources
[S1] https://www.hildredcapital.com (as of 2026-01-07)
[S2] https://www.hildredcapital.com/portfolio (as of 2026-01-07)
[S3] https://www.hildredcapital.com/news (as of 2026-01-07)
Frequently asked questions
Does Hildred Capital buy healthcare businesses?
Yes, the firm invests exclusively in healthcare businesses based on its publicly disclosed portfolio [S2]. All fourteen portfolio companies operate in healthcare subsectors including medical aesthetics, diagnostics, pharmaceuticals, physical therapy, dermatology, and healthcare technology [S2].
What companies has Hildred Capital acquired recently?
Recent acquisitions include OrangeTwist in January 2026, Tebra in December 2025, and AleraCare with Pure Healthcare in November 2025 [S3]. These transactions demonstrate continued investment activity through the firm’s most recent fund vintage.
Where is Hildred Capital based and how big is the firm?
The firm operates from New York City, NY, and manages approximately $4 billion in assets as of January 2026 [S1]. The firm closed its third flagship fund, Hildred Equity Partners III, in January 2025 [S3].
Is Hildred Capital still actively acquiring?
Yes, the firm completed three platform acquisitions between November 2025 and January 2026, indicating active deployment [S3]. The January 2025 close of Hildred Equity Partners III suggests the firm has capital available for new investments [S3].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.